FDA regulatory lawyer Melissa Mannion joins Jones Day in Washington - jonesday.com
FDA regulatory lawyer Melissa Mannion joins Jones Day in Washington, D.C., potentially signaling increased legal capacity for FDA-related matters.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 9, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Pharmaceutical manufacturers and related entities in the FDA/DEA space. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not applicable.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
A notable FDA regulatory lawyer has moved to a major law firm, which may affect the legal landscape but does not directly change regulations.
Who it affects
Pharmaceutical manufacturers and related entities in the FDA/DEA space.
What you must do
No immediate action required; monitor for any shifts in FDA enforcement or legal strategies.
Deadline
Not applicable.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- FDA moves to expose hidden foreign drug factories, strengthen domestic production in sweeping rule proposal - foxbusiness.com
- The FDA let substandard factories ship these medications to the U.S. - michiganadvance.com
- Tom’s of Maine says it will remedy mold, bacteria problems found by FDA at Sanford plant - mainebiz.biz
- The FTC Challenges Companies’ Allegedly Improper Orange Book Patent Listings - skadden.com
- Alabama Board of Medical Examiners Issues Warning of Non-FDA-Approved Peptides - drugtopics.com